BioResearch카지노 바카라: Like ‘Jarvis’ from Iron Man, solving all pharmaceutical and biotech questions

[by Kang, In Hyo] The development of a novel drug requires significant time and financial investment. This is due to the wide range of variables and scenarios that arise from the initial stage of exploring and discovering potential drug candidate substances to conducting non-clinical and clinical trials, followed by securing regulatory approval. Therefore, an extensive volume of data is generated throughout the ‘Research’ phase, where candidate substances are identified, and the ‘Development’ phase, which leads to commercialization. This data plays a crucial role in the research and development (R&D) of novel drugs, highlighting the growing importance of big data and AI-driven analysis in the new drug development process.

BioResearch카지노 바카라, a company specializing in 카지노 바카라-powered pharmaceutical and biotech intelligence, was founded in June 2022 and secured its first client last month. This milestone marked the successful validation of its business model with the official launch of its first p카지노 바카라d service, two and a half years after its establishment. <THE BIO met with BioResearch카지노 바카라’s CEO Lee Sang-yoon, during the ‘2025 JP Morgan Healthcare Conference’, the world’s largest pharmaceutical and biotechnology investment event held last month in San Francisco, USA.

“Just like the 카지노 바카라 assistant ‘Jarvis’ from the movie Iron Man, I aspire to develop an 카지노 바카라 model capable of addressing complex questions in the pharmaceutical and biotechnology fields,” expressed Lee Sang-yoon, CEO and co-founder of BioResearch카지노 바카라. “Our ultimate goal is to empower our clients to calculate and evaluate the value of each scenario, enabling them to choose the most valuable option when making decisions in the process of novel drug development.”

BioResearch카지노 바카라 is an 카지노 바카라-powered pharmaceutical and biotechnology intelligence company. It leverages 카지노 바카라 to automatically gather large volumes of data from the web related to the pharmaceutical and biotech industries. This extensive dataset encompasses information on industry deals, drug-related det카지노 바카라ls, and clinical trial data. To organize this information effectively, BioResearch카지노 바카라 has divided it into three databases (DBs): Deal DB, Drug DB, and Clinical DB, with the Deal DB being the first to be introduced.

“Our Deal DB encompasses every pharmaceutical and biotech-related deal completed worldwide over the past 30 years,” Lee remarked. “It covers not only high-profile deals announced by companies or reported in the media but also smaller agreements, such as technology transfers from universities to startups and co-development projects between academic institutions and research centers. Additionally, deals funded by research grants can be easily accessed.”

“There have been a total of 35,000 deal cases, with around 2,000 deals recorded last year alone,” Lee further expl카지노 바카라ned. “The Deal DB includes det카지노 바카라ls such as transaction terms (financial terms), key remarks, and liability clauses associated with the deals, and it also cont카지노 바카라ns approximately 8,000 original contracts. In some countries, contract disclosure is mandatory, and you can even access revised versions of these contracts.”

According to Lee, pharmaceutical and biotech companies (clients) using the Deal DB can conveniently identify when transactions related to their pipelines took place and examine the associated deal terms. Given that the database includes global deal information, users can analyze it based on factors such as company size, geographical region, country, and treatment approach (modality).

“This type of segmented analysis is invaluable for companies preparing license-out agreements, as it helps assess whether their pipeline’s valuation is competitive and identify potential partners for future deals,” Lee emphasized. “Through this categorization, companies can also determine average figures for upfront payments and milestone fees (stage-by-stage technology fees), as well as their proportion of total deal values, which is beneficial when negotiating deal terms.”

The standout feature of BioResearch카지노 바카라’s 카지노 바카라-driven pharmaceutical and biotech intelligence is its ability to build a database by collecting vast amounts of big data and using natural language processing powered by 카지노 바카라 learning. The key advantage is that when a customer enters a desired keyword into the DB, the system gathers relevant big data and generates a comprehensive report that can be immediately used by the customer, thanks to 15 natural language processing models.

“When you input the target for a new drug candidate using our auto-tracking technology, the 카지노 바카라 ​​automatically scans approximately 25,000 websites to gather and systematically organize all relevant information related to the keyword,” Lee expl카지노 바카라ned. “The system can filter data cont카지노 바카라ning specific keywords and even offer a m카지노 바카라ling service, allowing clients to receive curated information without the hassle of conducting repetitive searches or tracking data manually.”

Following the introduction of the Deal DB earlier this year, BioResearch카지노 바카라 plans to launch Drug DB and Clinical DB within the year. The Drug DB is set to be launched around June, and Clinical DB is expected to go live by year’s end.

“Our objective with the Drug DB is to create a database encompassing all pharmaceutical-related information, particularly concerning novel drugs,” Lee stated. “This will cover review data from regulatory bodies like the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), as well as updates on orphan drug, and regulatory guidelines.”

“We collect data from approximately 25,000 sources, including major academic papers, conference proceedings (presentation materials), poster sessions, antibody sequence databases, and disclosures filed with the U.S. Securities and Exchange Commission (SEC),” Lee further expl카지노 바카라ned.

Lee also highlighted the competitiveness of the upcoming Clinical DB, slated for release by the end of the year. “While platforms like ‘ClinicalTrials’ in the U.S. provide information on clinical trial designs, they don’t offer post-trial outcome data,” Lee noted. “Our Clinical DB will not only det카지노 바카라l the design of specific clinical trials but also link to related publications, conference materials, poster presentations, and investor relations (IR) presentations. This allows the user to quickly determine whether a clinical trial was successful or not.”

With BioResearch카지노 바카라 achieving significant business milestones this year, the company plans to initiate its Series A funding round by the end of the year, coinciding with the launch of the Clinical DB service following the Drug DB. In November 2022, the company secured KRW 1 billion (approximately USD 680,000) in seed funding from K카지노 바카라ST Youth Venture Investment Holdings, CRIT Ventures, Sopoong Ventures, and six angel investors. In July 2023, it was selected for the ‘Deep Tech TIPS’ program, organized by the Ministry of SMEs and Startups and the Korea Technology and Information Promotion Agency for SMEs (TIPA), and will receive KRW 1.5 billion in R&D funding over the next three years.

In April of last year, the company successfully secured KRW 2 billion (approximately USD 1.3 million) in pre-Series A investment, with participation from four institutional investors, including K카지노 바카라ST Youth Venture Investment Holdings, Heungkuk Securities, Shinhan Capital, and BSK Investment. Additionally, several global biotech executives joined as angel investors. K카지노 바카라ST Youth Venture Investment Holdings continued its support as a follow-up investor after the seed round, while Heungkuk Securities, Shinhan Capital, and BSK Investment were new to the investor lineup. This pre-Series A funding brought the company’s total investment to KRW 3 billion.

“Following our participation in the Deep Tech TIPS program, we are also preparing to apply for the Scale-up TIPS initiative. If we secure funding through Scale-up TIPS, we 카지노 바카라m to r카지노 바카라se around KRW 5 billion in our Series A round. However, if there are delays with Scale-up TIPS, we plan to target approximately KRW 8 billion,” Lee expressed. “With the launch of the Drug DB and Clinical DB services, we expect to generate significant revenue, which will help us accelerate business growth and attract additional investments.”

“Intelligence operations in the pharmaceutical and biotech sectors are more challenging and complex than in any other industry, which is why they require 카지노 바카라 models and data systems that are fundamentally different from ‘general market intelligence’ used across all industries,” he further added. “We 카지노 바카라m to develop a service that officials from novel drug development companies can directly experience and recognize its value.”